Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trial

Murphy, Alexander D, Porter, Catharine ORCID: https://orcid.org/0000-0003-1851-0677, White, Ann, Irving, Alys, Adams, Richard ORCID: https://orcid.org/0000-0003-3915-7243, Ray, Ruby, Casbard, Angela ORCID: https://orcid.org/0000-0001-6241-3052, Mahmood, Reem D., Karanth, Suman, Zhou, Cong, Pugh, Julia, Wheeler, Chelsey, Roberts, Victoria, Arnetoli, Giorgio, Salih, Zena, Hasan, Jurjees, Mitchell, Claire, Morgan, Robert D., Clamp, Andrew R. and Jayson, Gordon C. 2024. Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trial. International Journal of Gynecological Cancer 34 , pp. 1034-1040. 10.1136/ijgc-2024-005455

PDF - Accepted Post-Print Version Download (804kB)

Abstract

Objective: Cytotoxic chemotherapy for ovarian cancer can be augmented by co-administration of vascular endothelial growth factor inhibitors but these are contraindicated in patients with bowel obstruction due to the risk of gastrointestinal perforation. We evaluated the safety and feasibility of paclitaxel plus cediranib to treat patients with platinum-resistant ovarian cancer at risk of malignant bowel obstruction. Methods: A phase II trial included eligible patients between March 2018 and February 2021, identified by clinical symptoms and radiographic risk factors for malignant bowel obstruction. Cediranib (20 mg/day) was added to paclitaxel (70 mg/m2/week) within 9 weeks of starting paclitaxel if pretreatment bowel symptoms had improved. The primary endpoint was the number of patients treated for ≥5 days with cediranib that were free of grade 3–5 gastrointestinal perforation or fistula. Secondary endpoints were hospitalization for bowel obstruction, grade ≥3 adverse events, treatment compliance assessed by relative dose intensity, objective response, progression-free survival, and overall survival. Results: Thirty patients were recruited. Of these, 12 received paclitaxel alone and 17 received paclitaxel and cediranib in combination. One patient died before starting treatment. No patient developed a grade 3–5 gastrointestinal perforation or fistula (one sided 95% confidence interval (CI) upper limit 0.16). One patient required hospitalization for bowel obstruction but recovered with conservative management. The most common cediranib-related grade ≥3 adverse events were fatigue (3/17), diarrhorea (2/17), and hypomagnesemia (2/17). Relative dose intensity for paclitaxel was 90% (interquartile range (IQR) 85–100%; n=29) and for cediranib 88% (IQR 76–93%; n=17). The objective response in patients who received paclitaxel and cediranib was 65.0% (one complete and 10 partial responses). Median progression-free survival was 6.9 months (95% CI 4.4–11.5 months; n=17) and overall survival was 19.4 months (95% CI 10.1–20.4 months; n=17). Median follow-up was 12.4 months (8.9–not reached; n=17). Conclusions: The unexpectedly high withdrawal rate during paclitaxel alone, before introducing cediranib, meant we were unable to definitely conclude that paclitaxel plus cediranib did not cause gastrointestinal perforation or fistula. The regimen was however tolerated. Trial registration number: EudraCT 2016-004618-93

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine Centre for Trials Research (CNTRR)
Publisher:	BMJ Publishing Group
ISSN:	1048-891X
Date of First Compliant Deposit:	29 May 2024
Date of Acceptance:	25 April 2024
Last Modified:	08 Nov 2024 06:15
URI:	https://orca.cardiff.ac.uk/id/eprint/169252

Actions (repository staff only)

Edit Item